Amino-benzothiazole derivatives
    1.
    发明授权
    Amino-benzothiazole derivatives 失效
    氨基苯并噻唑衍生物

    公开(公告)号:US06407122B1

    公开(公告)日:2002-06-18

    申请号:US09554612

    申请日:2000-06-01

    IPC分类号: A61K31445

    CPC分类号: C07D417/06

    摘要: The present invention relates to amino-benzothiazole compounds of formula (I) wherein X, Y, Z and R1 are as defined in the specification, their pharmaceutically acceptable salts, processes for their preparation, pharmaceutical composition comprising such compounds and their use as neuroprotective agents.

    摘要翻译: 本发明涉及式(I)的氨基 - 苯并噻唑化合物,其中X,Y,Z和R 1如说明书中所定义,其药学上可接受的盐,其制备方法,包含这些化合物的药物组合物及其作为神经保护剂的用途 。

    Disubstituted piperidine derivatives as neuroprotective agents
    2.
    发明授权
    Disubstituted piperidine derivatives as neuroprotective agents 失效
    二取代哌啶衍生物作为神经保护剂

    公开(公告)号:US5968955A

    公开(公告)日:1999-10-19

    申请号:US43906

    申请日:1998-03-31

    CPC分类号: C07D413/06

    摘要: A Disubstituted piperidine compounds of formula (I), wherein R.sub.1 is hydrogen; bromo; chloro; a linear or branched C.sub.1 -C.sub.5 alkyl group; a linear or branched C.sub.1 -C.sub.5 alkoxy group; or an optionally substituted phenyl group; R.sub.2 is hydrogen, a linear or branched C.sub.1 -C.sub.5 alkyl group or an optionally substituted phenyl group; X is CH.sub.2, C.dbd.O, CHOH or C.dbd.NOH; R.sub.3 is hydrogen or a linear or branched C.sub.1 -C.sub.5 alkyl group; Y is a (CH.sub.2).sub.n group in which n is an integer from 0 to 4, CHOH, C.dbd.O or CH-A wherein A is an optionally substituted phenyl group; A is an optionally substituted phenyl group; W is hydrogen or hydroxy; stereoisomers thereof and their pharmaceutically acceptable salts. The compounds possess selective neuroprotective activity and are useful in the treatment of an acute or a degenerative CNS disease. A process is described for preparing the compounds and pharmaceutical compositions containing them.

    摘要翻译: PCT No.PCT / EP95 / 04075第 371日期1998年3月31日 102(e)1998年3月31日PCT PCT 1996年9月16日PCT公布。 公开号WO97 / 13769 日期1997年4月17日A式(I)的二取代哌啶化合物,其中R 1是氢; 溴 氯 直链或支链C 1 -C 5烷基; 直链或支链C 1 -C 5烷氧基; 或任选取代的苯基; R2是氢,直链或支链C1-C5烷基或任意取代的苯基; X是CH 2,C = O,CHOH或C = NOH; R3是氢或直链或支链C1-C5烷基; Y为(CH 2)n基团,其中n为0至4的整数,CHOH,C = O或CH-A,其中A为任选取代的苯基; A是任选取代的苯基; W是氢或羟基; 其立体异构体及其药学上可接受的盐。 该化合物具有选择性神经保护活性,可用于治疗急性或退行性CNS疾病。 描述了制备含有它们的化合物和药物组合物的方法。

    Substituted kynurenines and process for their preparation
    4.
    发明授权
    Substituted kynurenines and process for their preparation 失效
    替代的犬尿苷及其制备方法

    公开(公告)号:US5786508A

    公开(公告)日:1998-07-28

    申请号:US411656

    申请日:1995-04-06

    CPC分类号: C07C229/36 C07C2101/14

    摘要: The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT). The present invention also provides, as novel compounds, a selected class of KAT inhibitors which are the compounds of formula (IA) ##STR1## wherein R is halogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.6 -C.sub.10 aryloxy, phenyl-C.sub.1 -C.sub.4 alkoxy or trifluoromethyl, and R.sub.1 is hydroxy, C.sub.1 -C.sub.6 alkoxy, amino, mono-C.sub.1 -C.sub.6 alkylamino, di-C.sub.1 -C.sub.6 alkylamino, hydroxylamino, C.sub.1 -C.sub.4 alkoxyamino or benzyloxyamino, with the provisos that: (i) when R.sub.1 is hydroxy and, at the same time, R is halogen, then this halogen is not fluorine; and (ii) when R.sub.1 is hydroxy and, at the same time, R is C.sub.1 -C.sub.6 alkyl, then this C.sub.1 -C.sub.6 alkyl is not methyl, either as a single isomer or as a mixture of isomers, and the pharmaceutically acceptable salts thereof.

    摘要翻译: PCT No.PCT / US94 / 07804 Sec。 371日期:1995年4月6日 102(e)日期1995年4月6日PCT 1994年7月15日PCT公布。 公开号WO95 / 04714 日期1995年2月16日本发明涉及用作治疗与作为犬尿氨酸转氨酶(KAT)酶抑制剂的化合物的脑老化过程和围产期脑疾病相关的认知障碍的用途。 本发明还提供作为新化合物的选择类别的作为式(IA)化合物的KAT抑制剂,其中R是卤素,C 1 -C 6烷基,C 5 -C 7环烷基,苯基-C 1 -C 4烷基, C 1 -C 6烷氧基,C 6 -C 10芳氧基,苯基-C 1 -C 4烷氧基或三氟甲基,R 1是羟基,C 1 -C 6烷氧基,氨基,单-C 1 -C 6烷基氨基,二-C 1 -C 6烷基氨基,羟基氨基,C 1 -C 4 烷氧基氨基或苄氧基氨基,条件是:(ⅰ)当R 1为羟基,同时R为卤素时,该卤素不为氟; 和(ii)当R 1是羟基,并且同时R是C 1 -C 6烷基时,则该C 1 -C 6烷基不是甲基,作为单一异构体或作为异构体的混合物,以及其药学上可接受的盐 。

    4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
    5.
    发明授权
    4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity 失效
    具有犬尿氨酸-3-羟化酶抑制活性的4-苯基-4-氧代 - 丁酸衍生物

    公开(公告)号:US06323240B1

    公开(公告)日:2001-11-27

    申请号:US09068016

    申请日:1998-05-01

    IPC分类号: A61K31195

    摘要: 4-phenyl-4-oxo-butanoic acid derivatives for use in the treatment of the human or animal body by therepy; particularly as kynurenine-3-hydroxylase inhibitors, in the prevention and/or treatment of a neurodegenerative disease wherein the inhibition of such an enyzme is needed. The present invention further comprises a selected class of the above mentioned 4-phenyl-4-oxo-butanoic acid derivatives, their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them.

    摘要翻译: 4-苯基-4-氧代 - 丁酸衍生物,用于通过该药物治疗人体或动物体; 特别是作为犬尿氨酸-3-羟化酶抑制剂,在预防和/或治疗需要抑制这种乙烯的神经变性疾病中。 本发明还包括所选类别的上述4-苯基-4-氧代 - 丁酸衍生物,其药学上可接受的盐,其制备方法和含有它们的药物组合物。

    5-(3-Phenyl-3-oxo-propyl)-1H-tetrazole derivatives
    6.
    发明授权
    5-(3-Phenyl-3-oxo-propyl)-1H-tetrazole derivatives 失效
    5-(3-苯基-3-氧代 - 丙基)-1H-四唑衍生物

    公开(公告)号:US6133302A

    公开(公告)日:2000-10-17

    申请号:US446895

    申请日:1999-12-30

    CPC分类号: C07D257/04

    摘要: 5-(3-phenyl-3-oxo-propyl)-1H-tetrazole derivatives of formula (I) wherein each of R and R.sub.1, being the same or different, is hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, phenyl, benzyl, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, SOR.sub.4 or SO.sub.2 R.sub.4 wherein R.sub.4 is C.sub.1 -C.sub.6 alkyl, --N(R.sub.5 R.sub.6) in which each of R.sub.5 and R.sub.6 is, independently, hydrogen, C.sub.1 -C.sub.6 alkyl, formyl or C.sub.2 -C.sub.6 acyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, benzyl, phenyl; R.sub.3 is hydrogen, hydroxy, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, benzyl, phenyl or a group --N(R.sub.7 R.sub.8) in which each of R.sub.7 and R.sub.8 is, independently, hydrogen, C.sub.1 -C.sub.4 alkyl, benzyl, phenyl, or one of R.sub.7 and R.sub.8 is hydrogen and the other is COR.sub.9 wherein R.sub.9 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, phenyl or a group --N(R.sub.10 R.sub.11) in which R.sub.10 and R.sub.11 are, each independently, hydrogen or C.sub.1 -C.sub.4 alkyl or, taken together, R.sub.2 and R.sub.3 form a carbocyclic C.sub.3 -C.sub.6 ring; and pharmaceutically acceptable salts thereof have kynurenine-3-hydroxylase enzyme inhibitory activity. ##STR1##

    摘要翻译: PCT No.PCT / EP98 / 04032 Sec。 371 1999年12月30日第 102(e)1999年12月30日PCT PCT。1998年6月25日PCT公布。 公开号WO99 /​​ 02506 日本1月21日,19995-(3-苯基-3-氧代 - 丙基)-1H-四唑衍生物,其中R和R 1相同或不同,为氢,卤素,羟基,三氟甲基, 氰基,硝基,苯基,苄基,C1-C6烷基,C1-C6烷氧基,C1-C6烷硫基,SOR4或SO2R4,其中R4是C1-C6烷基,-N(R5R6),其中R5和R6各自独立地为 氢,C 1 -C 6烷基,甲酰基或C 2 -C 6酰基; R2是氢,C1-C6烷基,C1-C6烷氧基,苄基,苯基; R3是氢,羟基,C1-C6烷基,C1-C6烷氧基,苄基,苯基或基团-N(R7R8),其中R7和R8各自独立地是氢,C1-C4烷基,苄基,苯基或 R 7和R 8中的一个是氢,另一个是COR 9,其中R 9是氢,C 1 -C 4烷基,C 1 -C 4烷氧基,苯基或基团-N(R 10 R 11),其中R 10和R 11各自独立地是氢或C1- C4烷基或一起为R2和R3形成碳环C 3 -C 6环; 及其药学上可接受的盐具有犬尿氨酸-3-羟化酶抑制活性。

    Substituted kynurenines and process for their preparation
    10.
    发明授权
    Substituted kynurenines and process for their preparation 失效
    替代的犬尿苷及其制备方法

    公开(公告)号:US5519055A

    公开(公告)日:1996-05-21

    申请号:US102843

    申请日:1993-08-06

    摘要: The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT).The present invention also provides, as novel compounds, a selected class of KAT inhibitors which are the compounds of formula (IA) ##STR1## wherein R is halogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.6 -C.sub.10 aryloxy, phenyl-C.sub.1 -C.sub.4 alkoxy or trifluoromethyl, andR.sub.1 is hydroxy, C.sub.1 -C.sub.6 alkoxy, amino, mono-C.sub.1 -C.sub.6 alkylamino, di-C.sub.1 -C.sub.6 alkylamino, hydroxylamino, C.sub.1 -C.sub.4 alkoxyamino or benzyloxyamino; with the provisos that(i) when R.sub.1 is hydroxy and, at the same time, R is halogen, then this halogen is not fluorine; and(ii) when R.sub.1 is hydroxy and, at the same time, R is C.sub.1 -C.sub.6 alkyl, then this C.sub.1 -C.sub.6 alkyl is not methyl, and the pharmaceutically acceptable salts thereof.

    摘要翻译: 本发明涉及用于治疗与脑衰老过程相关的认知障碍和围产期脑疾病的化合物的用途,所述化合物作为犬尿氨酸转氨酶(KAT)酶的抑制剂。 本发明还提供作为新化合物的选定类别的KAT抑制剂,其是式(IA)化合物其中R是卤素,C 1 -C 6烷基,C 5 -C 7环烷基,苯基-C 1 -C 6烷基, C4烷基,C1-C6烷氧基,C6-C10芳氧基,苯基-C1-C4烷氧基或三氟甲基,R1为羟基,C1-C6烷氧基,氨基,单C1-C6烷基氨基,二C1-C6烷基氨基, C1-C4烷氧基氨基或苄氧基氨基; 条件是(i)当R 1是羟基,同时R是卤素时,该卤素不是氟; 和(ii)当R 1是羟基,并且同时R是C 1 -C 6烷基时,则该C 1 -C 6烷基不是甲基,及其药学上可接受的盐。